Drugs / TAF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03434353 | Feb 2018 → Jan 2020 | chronic hepatitis B virus infection | Gilead Sciences | Terminated | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03434353 ↗ |
| Route | Oral | “Administered orally once daily with food” NCT03434353 ↗ |